Skip to main content
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. — Investor Relations & Filings

Ticker · PTHS ISIN · US1711261057 US Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2024-02-20 Capital/Financing Update
Country US United States of America
Listing US PTHS

About Pelthos Therapeutics Inc.

https://ir.pelthos.com/

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for patients with unmet medical needs. Its lead product is ZELSUVMI™ (berdazimer topical gel, 10.3%), the first FDA-approved, at-home prescription treatment for molluscum contagiosum. ZELSUVMI is based on the company's proprietary nitric oxide-releasing technology platform, NITRICIL™, which is also being utilized for a pipeline of other product candidates. The company's portfolio also includes the acquired asset Xepi (ozenoxacin) Cream, 1%.

Recent filings

Filing Released Lang Actions
424B4
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(4) related to an initial public offering (IPO) of Chromocell Therapeutics Corporation. It includes information about the offering of common stock, underwriting details, reverse stock split, share issuance, and other capital structure changes. The document is not a financial report, earnings release, or management discussion but rather a capital markets filing related to fundraising and share issuance. The presence of terms like 'prospectus', 'initial public offering', 'underwriters', 'shares offered', and 'registration statement' clearly indicates this is a Capital/Financing Update. The document length is substantial and contains detailed offering information, consistent with a capital raising filing rather than a simple announcement or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-02-20 English
POS EX
Regulatory Filings Classification · 100% confidence The document is a Post-Effective Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC. It references Rule 462(d) under the Securities Act of 1933 and updates an exhibit related to the registration statement. The document is a regulatory filing related to securities registration and amendments, not a financial report, earnings release, or other report types. It is a formal SEC filing updating registration details, which fits the category of Regulatory Filings (RNS). The document length is about 6,000 characters, and it does not contain financial statements or detailed financial data, so it is not a financial report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-02-16 English
Director's Dealing 2024
Director's Dealing
2024-02-16 English
Director's Dealing 2024
Director's Dealing
2024-02-16 English
Director's Dealing 2024
Director's Dealing
2024-02-16 English
Director's Dealing 2024
Director's Dealing
2024-02-16 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.